Kimberly Lenz, PharmD, clinical pharmacy manager, MassHealth/Office of Clinical Affairs, University of Massachusetts Medical School discusses initiatives introduced to implement appropriate opioid prescribing, best practices for enforcing appropriate prescribing, and if current opioid restrictions have reduced utilization.
Kimberly Lenz, PharmD, clinical pharmacy manager, MassHealth/Office of Clinical Affairs, University of Massachusetts Medical School discusses initiatives introduced to implement appropriate opioid prescribing, best practices for enforcing appropriate prescribing, and if current opioid restrictions have reduced utilization.
Transcript
What initiatives have been introduced to implement appropriate opioid prescribing?
When you look across both our plan, as well as other plans across the nation, I think the majority of health plans implement dose limits, quantity limits, duplicate restrictions, and things of that nature, but it really is a wide variety of different plans and initiatives that plans use. Other plans, like ours, use a therapeutic class management program where a multidisciplinary team comes together to reach out to prescribers and discuss treatment plans.
What are best practices to enforce appropriate opioid prescribing?
I think most programs end up using prior authorization because inevitably that’s the tool we have to use, but I think the best approach really is using that in combination with that multidisciplinary team, who’s going to work with the provider hand in glove to kind of decide on safe prescribing, as well as what they think is best for the patient.
Have current opioid restrictions decreased opioid utilization?
It’s a great question, and I’m glad you asked that, because we actually just looked at that in our program. So, I can speak directly to our program, and yes it has worked. So, when we looked over the last 15 years, with our partners at the drug utilization review program at UMass Medical School, we did find a sustained decrease in the average daily dose of our patients who were on high doses of opioids after 3 sequential dose reductions. So right now, we have a high dose limit of 120mg of morphine equivalents, and again, over those 15 years we did see sustained decreases.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More